These differences in mutational status are not clear but may be a result of chemotherapy or reflect different cancer cells’ pre-chemotherapy KRAS dependence.41 Interestingly, M-EOC patients were found to have a 3-fold lower median CTCEpCAM count following chemotherapy treatment compared to chemotherapy naïve patients, while CTCFAPα median counts for these cohorts remained unchanged, potentially suggesting CTCEpCAM were more sensitive to chemotherapy. This evidence concerns the gene KRAS and cancer.